View
215
Download
0
Embed Size (px)
Citation preview
C4d – The Birmingham UK Experience
Desley Neil, Majid Mukadam, David Briggs*UHBNHSFT, NHSBT*
Birmingham
Method
• C4d staining performed routinely on all EMBs from May 2004.• May 2004 – May 2008
– 1443 biopsies in 163 patients with 166 transplants– reports for Grade of C4d staining
• 71 (4.9%) unreported – 14 missing , rest graded• Presence or absence DSA (luminex bead) – not routine• C3d staining on strong C4d cases• Pattern of inflammation reassessed in
• Strong C4d bx V highest C4d neg/weak• Busy, no, focal or diffuse infiltrate, Cells in / around capillary
Biopsy protocol• Protocol
– Weekly x 6– Fortnightly x 2– Monthly x 2– 6 weekly x 2 1year– 6 monthly x2 2 years– Yearly x1 3 years
• Indication– Symptomatic or change in echo
• Change of medication– 2-3 biopsy during transition and once established
C4d (& C3d) grading system
• 0 Negative• 1 Weak patchy staining• 2 Moderate staining• 3 Diffuse strong staining
(Looks like CD31 at low power)
• Immunoperoxidase Polyclonal Ab Biomedica
C4d
C3d
Demographics
49 (14-65)49 (14-63) 44 (19-65) Age
132 31 163
Biopsies
• Timing of biopsies– 171 days (0-5806 days) post-tx
• Number of biopsies / patient– 4 (1-40) biopsies
C4d staining
72%
15%
60%
Highest C4d grade / patient
12.3%
35.6%
22.1%29.5%
Death related to highest C4d6.3% 11.1% 20.7% 35%
Kruskal Wallis p<0.02
20.0015.0010.005.000.00
followup
1.0
0.8
0.6
0.4
0.2
0.0
Cu
m S
urv
ival
3-censored
2-censored
1-censored
0-censored
3
2
1
0highestC4d
Survival Functions
Follow up time v highest C4d grade
Follow up 0 1 2 3 missing
N= 48 36 58 20 1
Median(range) 8 yrs
(0.4-16.8)4.4 yrs(0.5-15.5)
3.6yrs(0.3-14.8)
6 yrs(0.6-15.6)
12.4yr
Kruskal Wallis p=0
Strong C4d
• 20 patients• 7 had DSA found• 6/7 (85.7%) with DSA died• 1 with lot of consecutive strong C4d
– serum not sent till after Plasma exchange = negative
– Retransplanted
• Others only HLA Ab tested inconsistently
DSA
• 19 (11.7%) patients• Found 7.1 (0-12.9) years post-tx• 13 (68.6%) class II and 6 (31.4%) class I and II
Demographics of DSA +/-
Age: DSA + 46 (14-59) DSA – 49 (17-65)
NS
Symptoms
• 5 (26.3%) asymptomatic• 14 (73.3%) symptomatic
– 3 IHD/graft vasculopathy– 11 syncope, heart failure
• 10 evidence of graft vasculopathy• 8 no evidence of graft vasculopathy• 1 don’t know
Death related to DSA47.4%18.8%10.5%
Death v DSA Wilcoxin p=0.000
Follow up time v DSA
Not tested Neg PosN= 19 125 19
Median(range) 6.1 yrs
(0.4-15.7)5.2 yrs(0.3-15.8)
8.6yrs(0.9-13.5)
Kruskal Wallis NS
Death8.8 (3-12.9) yrs post tx215 (7-1188) days post DSA found
DSA v highest C4d grade
Kruskal Wallis p=0
35%17.2%2.8%2.1%
DSA v Strong C4d +C3d grade
DSA /Patient with strong C4d +/- mod/strong C3d
60%
P<0.05
DSA in relation to C4d persistence
• Persistent strong 4/6 (66.7%)• Intermittent mod/strong 4/17 (23.5%)• Single strong (others neg/weak) 4/18 (22.2%)• Single bx = strong (no others bx) 3/7 (42.9%)• Nothing much 3/111 (2.7%)
Kruskal-Wallis p<0.02
C3d staining in relation to persistence of C4d
N=357 neg/weakN=42 strong
BUSY “B” PATTERN
Summary• C4d staining relatively uncommon• Both DSA and highest grade of C4d correlates with
death• Correlation between C4d and DSA –? improved by
C3d• Neither C4d or DSA in isolation is sensitive at a
single time point – C4d - comes and goes, precede inflam and symptoms– Repeat DSAs (- to + in 4/7)
• Using ISHLT criteria will miss 2/3 C4d positive cases
• same also if C3d mod/strong• Busy “B” with cells in or around vessels• C4d/C3d needs to be routine
C4d grade